S1PR1

European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

Retrieved on: 
Monday, May 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Clinical trials, Immunosuppressants, Medical specialties, Multiple sclerosis, Immunology, Medicine, Nitriles, Teriflunomide, Sphingosine-1-phosphate, Janssen Pharmaceuticals, Ponesimod, S1PR1, Sphingosine-1-phosphate receptor modulator, Multiple Sclerosis, PONVORY (ponesimod), the Janssen Pharmaceutical Companies of Johnson & Johnson, MULTIPLE SCLEROSIS, PONVORY (PONESIMOD), THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.
  • Janssen Receives Positive CHMP Opinion for PONVORY (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features.
  • 11 DAmbrosio D, Feedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.

Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Retrieved on: 
Tuesday, March 23, 2021
Finance, SVB Leerink, G protein-coupled receptors, Companies, Money, ADSS, S1PR1, Underwriting, Sphingosine-1-phosphate, Jefferies Group, S1P, Public offering

The number of ADSs issued at closing included the exercise in full of the underwriters option to purchase 1,687,500 additional ADSs from the Company at the initial public offering price, less underwriting discounts and commissions.

Key Points: 
  • The number of ADSs issued at closing included the exercise in full of the underwriters option to purchase 1,687,500 additional ADSs from the Company at the initial public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering were approximately US$219.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
  • Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corporation Hong Kong Securities Limited acted as joint book-running managers for the offering.
  • Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

Study Reveals Details of Immune Defense Guidance System

Retrieved on: 
Wednesday, March 3, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, Lipids, Sphingosine-1-phosphate, G protein-coupled receptors, T cell, Inflammation, CD69, S1PR1

Past studies had shown that the immune system regulates the concentration of the molecule, sphingosine 1 phosphate (S1P), in order to draw cells to the right locations.

Key Points: 
  • Past studies had shown that the immune system regulates the concentration of the molecule, sphingosine 1 phosphate (S1P), in order to draw cells to the right locations.
  • S1P concentration gradients, for instance, can guide immune T cells to either stay in lymph nodes, connected glands in which these cells mature, or move into blood vessels.
  • Such activation of immune cells can cause inflammation, swelling, and/or death of targeted cells.
  • While past work had shown that S1P is produced by cells attached to lymph nodes, the new study found that monocytes, circulating immune cells, also produced it when mice were infected with a virus.